Recall Register

Food, drugs, devices › Allergan Sales, LLC

Device recall: Keller Funnel 2, REF: HA-001, STERILEEO, Rx Only,

FDA enforcement event 94287 · Class II · initiated 14 Mar 2024 · status Ongoing

DeviceVoluntary: Firm initiated1 product recordIrvine, CA

FDA enforcement event 94287 is a device recall by Allergan Sales, LLC of Irvine, CA, initiated 14 Mar 2024 and classified Class II, with 1 product record.

FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 87% of the 970 device enforcement events initiated in 2024 carry the same class.

Status: Ongoing. Initiation: voluntary: firm initiated. Allergan Sales, LLC has 8 enforcement events on this register, with a median of 2 product records per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Allergan Sales, LLC, Irvine, CA.

Reason for recall

"Their is a potential that breast implants lack the lubricious coating that allows them to slide through the funnels during the implantation procedure."

Distribution

"US Nationwide distribution including in the states of AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH,…"

Product records

Recall numberProductQuantityClassStatusReport date
Z-1694-2024Keller Funnel 2, REF: HA-001, STERILEEO, Rx Only,10837Class IIOngoing8 May 2024

Context

87%of 2024 device events are Class II970 events that year
1product record in this eventfirm median: 2
8events on this register for the firm

Other enforcement events for Allergan Sales, LLC

InitiatedProduct (first record)TypeClassRecords
19 Mar 2019Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% 5 mL bottles, Rx only, Allergan, Inc. IrviDrugClass II1
19 Oct 2017Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-DrugClass III2
1 May 2017Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile, 3.5 g tube, RX onlDrugClass II1
16 Mar 2017Lumigan (bimatoprost ophthalmic solution) 0.01%, 7.5 mL bottle, Rx only, Allergan Irvine, CA 92612, NDC 0023-3205-08.DrugClass III1
30 Jun 2016TAZORAC (tazarotene) Gel 0.05%, Rx only, For Dermatologic Use Only, Not for Ophthalmic Use, packaged in a) 30 g tubes (NDrugClass II2
10 May 2016Tazorac (tazarotene) Gel 0.05%, Rx only, packaged in a) 30g (NDC 0023-8335-03) and b) 100g (NDC 0023-8335-10) tubes, AllDrugClass II2
24 Aug 2015Refresh Lacri-Lube (Mineral Oil 42.5% and White Petrolatum 56.8%) Lubricant Eye Ointment, packaged in a) Net wt. 0.12 ozDrugClass II4

All 8 events for Allergan Sales, LLC

Questions and answers

Why was this device recalled?

FDA's record gives the reason for recall as: "Their is a potential that breast implants lack the lubricious coating that allows them to slide through the funnels during the implantation procedure."

What does Class II mean?

FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Where was the product distributed?

FDA's distribution pattern field reads: "US Nationwide distribution including in the states of AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH,…"

Is the recall still ongoing?

FDA lists the status as Ongoing. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA device enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.